drugset / Trial / NCT02187068

Dexmedetomidine Pharmacokinetics in the Obese

NCT02187068 ↗

Phase 4 Completed 40 enrolled Pontificia Universidad Catolica de Chile
RandomizedSingle-groupQuadruple-blindSupportive care

Summary

The aim of this study is to characterize, using two different modeling approaches, one based on purely statistic concept and one using a more mechanistic analysis, the influence of body weight and composition on the pharmacokinetic of dexmedetomidine.

Timeline

Start
2012-04
Primary completion
2012-12
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 0.25 ug/kg Intravenous
Subject Dexmedetomidine Other / unclassified 0.5 ug/kg Intravenous

Indications